Barclays
VTGN icon

Barclays’s VistaGen Therapeutics VTGN Stock Holding History

Barclays’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$4 – 5738
2025
Q3 		$4 Hold
1
– – ﹤0.01% 5421
2025
Q2 		$2 Hold
1
– – ﹤0.01% 5190
2025
Q1 		$3 Buy
+1
New +$3 ﹤0.01% 5206
2024
Q3 		– Sell
-19,261
Closed -$67K – 5494
2024
Q2 		$67K Sell
19,261
-3,816
-17% -$16.5K ﹤0.01% 4088
2024
Q1 		$122K Hold
23,077
– – ﹤0.01% 4356
2023
Q4 		$119K Buy
+23,077
New +$87.3K ﹤0.01% 4596
2023
Q2 		– Sell
-3,504
Closed -$13.1K – 5107
2023
Q1 		$13.1K Buy
3,504
+1,652
+89% +$8.66K ﹤0.01% 4714
2022
Q4 		$5.72K Buy
1,852
+1,577
+573% +$5.94K ﹤0.01% 4988
2022
Q3 		$1K Sell
275
-51
-16% -$505 ﹤0.01% 4711
2022
Q2 		$9K Sell
326
-724
-69% -$25.6K ﹤0.01% 4670
2022
Q1 		$40K Sell
1,050
-6,800
-87% -$296K ﹤0.01% 4203
2021
Q4 		$459K Buy
7,850
+5,203
+197% +$339K ﹤0.01% 3247
2021
Q3 		$218K Buy
2,647
+1,840
+228% +$160K ﹤0.01% 3582
2021
Q2 		$76K Buy
807
+135
+20% +$10K ﹤0.01% 3949
2021
Q1 		$43K Buy
+672
New +$44.9K ﹤0.01% 4236

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays's VTGN Position: Q4 2025 in Review

Barclays sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 1 share — an estimated $4 sold.

Barclays first reported a position in VTGN in Q1 2021 and held it in 15 quarters. The position peaked at $459K in Q4 2021. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Barclays reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 1 VistaGen Therapeutics share in Q4 2025, an estimated $4.
  • Barclays first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 15 quarters.
  • Barclays's VistaGen Therapeutics position peaked at $459K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.